Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A randomized crossover study of prophylactic immunoglobulin (IgG) therapy was performed in patients with chronic lymphocytic leukaemia (CLL) or non-Hodgkin's lymphoma (NHL). Twelve patients with hypogammaglobulinemia or a history of recurrent infections received infusions of IgG or placebo intravenously (IV) every 3 weeks for 1 year. They were then switched to the alternative preparation for another year. The number of serious bacterial infections was significantly less (P = .001; Mainland's cross-over method) in the months in which patients received IgG. Serious bacterial infections showed a trend to be associated with an IgG level less than 6.4 g/L (P = .046; Fisher's exact test).

Type

Journal article

Journal

Blood

Publication Date

02/1989

Volume

73

Pages

366 - 368

Keywords

Aged, B-Lymphocytes, Double-Blind Method, Humans, Immunization, Passive, Immunoglobulin G, Immunoglobulins, Intravenous, Infection, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Middle Aged, Prognosis, Random Allocation